Lantheus Holdings is engaged in the development, manufacture and commercialization of diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart disease, cancer and other diseases. Co.'s commercial products include DEFINITY, which is a microbubble ultrasound enhancing agent used in ultrasound exams of the heart, also known as echocardiography exams; and TechneLite, which is a Technetium (Tc-99m) generator that provides the nuclear material used by radiopharmacies to radiolabel Cardiolite, Neurolite and other Tc-99m-based radiopharmaceuticals used in nuclear medicine procedures.